AngioDynamics Inc

Healthcare US ANGO

9.2USD
-0.21(2.23%)

Last update at 2025-05-23T16:45:00Z

Day Range

9.189.34
LowHigh

52 Week Range

5.269.42
LowHigh

Fundamentals

  • Previous Close 9.41
  • Market Cap361.24M
  • Volume61019
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-13.17600M
  • Revenue TTM292.73M
  • Revenue Per Share TTM7.25
  • Gross Profit TTM 174.25M
  • Diluted EPS TTM-6.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Type yearly yearly yearly yearly yearly
Date 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Income before tax -54.43700M -29.94900M -36.05200M -167.13500M 59.47M
Minority interest - - - - -
Net income -52.44200M -26.54700M -31.54800M -165.78700M 61.34M
Selling general administrative 40.00M 38.45M 35.92M 37.87M 35.17M
Selling and marketing expenses 104.25M 95.30M 81.31M 78.63M 80.96M
Gross profit 174.25M 165.73M 156.79M 150.27M 191.87M
Reconciled depreciation 30.87M 29.35M 25.92M 23.80M 25.88M
Ebit -19.23300M -19.00700M -14.87000M -14.16700M 72.92M
Ebitda 11.64M 10.34M 11.05M 9.64M 98.80M
Depreciation and amortization 30.87M 29.35M 25.92M 23.80M 25.88M
Non operating income net other -0.55400M -0.79000M 0.09M -1.03700M -5.30600M
Operating income -19.23300M -19.00700M -14.87000M -14.16700M 21.43M
Other operating expenses 357.43M 334.44M 305.97M 278.19M 332.95M
Interest expense 2.70M 0.69M 0.86M 0.91M 5.10M
Tax provision -1.99500M -3.40200M -4.50400M -1.34800M -3.55600M
Interest income - - - 0.91M 5.10M
Net interest income -2.70200M -0.68800M -0.86100M -0.90700M -5.09900M
Extraordinary items - - - - 72.49M
Non recurring 32.50M 10.25M 20.32M 153.06M 8.35M
Other items - - - - -
Income tax expense -1.99500M -3.40200M -4.50400M -1.34800M -1.87100M
Total revenue 338.75M 316.22M 291.01M 264.16M 359.48M
Total operating expenses 192.93M 183.95M 171.75M 164.31M 165.34M
Cost of revenue 164.51M 150.49M 134.22M 113.89M 167.61M
Total other income expense net -35.20400M -10.94200M -21.18200M -152.96800M -13.45000M
Discontinued operations - - - - 72.49M
Net income from continuing ops -52.44200M -26.54700M -31.54800M -166.78700M -11.14600M
Net income applicable to common shares -52.44200M -26.54700M -31.54800M -166.78700M 61.34M
Preferred stock and other adjustments - - - - -
Breakdown 2024-05-31 2023-05-31 2022-05-31 2021-05-31 2020-05-31
Type yearly yearly yearly yearly yearly
Date 2024-05-31 2023-05-31 2022-05-31 2021-05-31 2020-05-31
Total assets 317.67M 532.64M 552.75M 561.44M 595.51M
Intangible assets 77.38M 111.14M 152.38M 168.98M 197.14M
Earning assets - - - - -
Other current assets 12.97M 4.62M 2.20M 1.76M 2.24M
Total liab 112.08M 154.34M 128.26M 121.98M 139.64M
Total stockholder equity 205.59M 378.30M 424.49M 439.46M 455.87M
Deferred long term liab - 12.81M 16.04M 19.95M 24.06M
Other current liab 50.91M 43.38M 21.46M 37.95M 2.13M
Common stock 0.39M 0.38M 0.38M 0.38M 0.37M
Capital stock 0.39M 0.38M 0.38M 0.38M 0.37M
Retained earnings -395.20400M -210.85500M -158.41300M -131.86600M -100.31800M
Other liab - 17.38M 24.20M 37.08M 39.55M
Good will 0.00000M 159.24M 201.06M 201.32M 201.51M
Other assets - 49.22M 10.96M 3.81M 5.19M
Cash 76.06M 44.62M 28.82M 48.16M 54.44M
Cash and equivalents - - - - -
Total current liabilities 91.16M 83.83M 74.32M 57.58M 51.53M
Current deferred revenue - -14.76100M 16.04M - 29.47M
Net debt -71.32800M 5.20M 4.96M -28.16100M -13.59900M
Short term debt 1.98M 14.76M 8.78M - 0.84M
Short long term debt 4.73M 14.76M 8.78M - 0.84M
Short long term debt total 5.91M 49.82M 33.78M 20.00M 40.84M
Other stockholder equity 604.77M 593.49M 581.16M 567.79M 557.16M
Property plant equipment - 44.38M 45.01M 37.07M 28.31M
Total current assets 193.25M 163.54M 143.34M 140.88M 152.91M
Long term investments - - - - -
Net tangible assets - 378.30M 71.05M 69.16M 57.22M
Short term investments - - - - -
Net receivables 43.61M 52.83M 52.30M 35.41M 31.26M
Long term debt - 49.82M 25.00M 20.00M 40.00M
Inventory 60.62M 55.33M 51.39M 48.61M 59.91M
Accounts payable 37.75M 40.45M 28.05M 19.63M 19.10M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -4.36500M -4.72300M 1.36M 3.15M -1.34100M
Additional paid in capital - - - - -
Common stock total equity - 0.38M 0.38M 0.38M 0.37M
Preferred stock total equity - - - - -
Retained earnings total equity - -210.85500M -158.41300M -131.86600M -100.31800M
Treasury stock - -5.71400M -5.71400M -5.71400M -5.71400M
Accumulated amortization - - - - -
Non currrent assets other 5.57M 54.33M -5.07400M 13.19M 15.64M
Deferred long term asset charges - - - - -
Non current assets total 124.42M 369.10M 409.41M 420.56M 442.60M
Capital lease obligations - - - - -
Long term debt total - 49.82M 25.00M 20.00M 40.00M
Breakdown 2024-05-31 2023-05-31 2022-05-31 2021-05-31 2020-05-31
Type yearly yearly yearly yearly yearly
Date 2024-05-31 2023-05-31 2022-05-31 2021-05-31 2020-05-31
Investments 123.72M -9.74600M -11.41000M -8.52400M -63.34500M
Change to liabilities - 2.14M 3.91M 4.88M -15.46700M
Total cashflows from investing activities - -9.74600M -19.30700M -13.71100M -63.34500M
Net borrowings - 24.25M 5.00M -20.00000M -93.27500M
Total cash from financing activities -64.24800M 25.42M 7.68M -16.98600M -95.24200M
Change to operating activities - 0.33M -5.01200M -3.18100M -6.15500M
Net income -184.34900M -52.44200M -26.54700M -31.54800M -165.78700M
Change in cash 31.44M 15.79M -19.33600M -6.27400M -173.20600M
Begin period cash flow 44.62M 28.82M 48.16M 54.44M 227.64M
End period cash flow 76.06M 44.62M 28.82M 48.16M 54.44M
Total cash from operating activities -28.15800M 0.08M -7.19400M 24.09M -14.55400M
Issuance of capital stock - - - - -
Depreciation 27.71M 30.87M 29.35M 25.92M 23.80M
Other cashflows from investing activities - -5.93400M -15.01000M -8.52400M -56.11000M
Dividends paid - - - - -
Change to inventory -9.41000M -8.19800M -2.79600M 11.54M -18.84500M
Change to account receivables 7.89M -1.29900M -17.15100M -4.16200M 11.92M
Sale purchase of stock - - - - -0.75900M
Other cashflows from financing activities -15.00000M 0.42M 2.68M -13.71100M 38.02M
Change to netincome - 28.50M 11.05M 23.00M 156.47M
Capital expenditures 5.77M 4.35M 4.30M 13.71M 7.58M
Change receivables - -1.29900M -17.15100M -4.16200M 11.92M
Cash flows other operating - 0.51M -6.28100M -5.53000M -5.65300M
Exchange rate changes - - - 0.33M -0.06500M
Cash and cash equivalents changes - 15.75M -18.81800M -6.27400M -173.20600M
Change in working capital 14.42M -7.02600M -21.04700M 9.07M -28.54900M
Stock based compensation 10.53M 11.16M 10.69M 8.62M 7.59M
Other non cash items 111.50M 19.82M 4.07M 16.83M 149.95M
Free cash flow -33.92600M -4.27400M -11.49100M 10.38M -22.13900M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ANGO
AngioDynamics Inc
-0.21 2.23% 9.20 - 96.15 1.23 1.78 1.03 -137.629
ISRG
Intuitive Surgical Inc
-2.37 0.44% 540.30 73.05 61.73 19.15 10.25 18.41 59.92
ESLOY
Essilor International SA
-6.24 4.21% 141.86 35.39 24.81 3.63 2.20 4.00 16.25
ESLOF
EssilorLuxottica Société anonyme
-8.81 3.04% 281.19 35.71 25.13 3.62 2.23 4.00 16.25
BDX
Becton Dickinson and Company
-1.88 1.09% 170.43 37.72 15.92 3.25 2.49 4.08 17.10

Reports Covered

Stock Research & News

Profile

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.

AngioDynamics Inc

14 Plaza Drive, Latham, NY, United States, 12110

Key Executives

Name Title Year Born
Mr. James C. Clemmer CEO, Pres & Director 1964
Mr. Stephen A. Trowbridge Exec. VP & CFO 1974
Mr. David D. Helsel Sr. VP of Global Operations and R&D 1964
Mr. Chad T. Campbell Sr. VP & GM of Vascular Access Global Bus. Unit 1971
Ms. Laura Piccinini Sr. VP & GM of International 1970
Mr. Richard C. Rosenzweig Sr. VP, Gen. Counsel & Company Sec. 1967
Mr. Benjamin H. Davis Sr. VP of Bus. Devel. 1964
Ms. Marna I. Bronfen-Moore Sr. VP of HR 1967
Mr. Warren G. Nighan Sr. VP of Quality & Regulatory Affairs 1969
Ms. Kim L. Seabury Sr. VP of Information Technology 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.